Chapter 17 : Immunization Against Viral Diseases

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Immunization Against Viral Diseases, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch17-1.gif /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch17-2.gif


Vaccines against viral infections are perhaps the greatest of all biomedical achievements for preventing disease and improving the public health. The most notable example is the success of smallpox vaccination. The practice of variolization (mechanical attenuation and intentional low-dose infection) to reduce the virulence of subsequent smallpox infection was started more than 1,000 years ago in India and China. However, smallpox vaccination was first performed by Jenner in 1796. This event marked the beginning of modern vaccine development and the first clinical test of vaccine efficacy. An expansive, sustained world health effort with global cooperation and leadership in combination with creative approaches, like the ring vaccination campaign, resulted in the 1980 WHO declaration that naturally occurring smallpox had been eradicated. Numerous other vaccines have had a significant impact on the severity and frequency of viral diseases, and many previously common viral illnesses are rarely encountered in modern clinical care (Table 1). In particular, vaccines against hepatitis A and B, poliovirus, measles, mumps, varicella, and rubella have markedly reduced the frequency of these infections in developed countries. Unfortunately, many of these infections remain major health problems, particularly in communities who choose to opt out of standard childhood immunizations (1) and in the developing world. A description of viral vaccines available for use in the United States is shown in Table 2.

Citation: Ledgerwood J, Graham B. 2017. Immunization Against Viral Diseases, p 351-370. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch17
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Eukaryotes have evolved mechanisms to detect potential microbial pathogens as they encounter the plasma membrane or penetrate the endosomal or cytoplasmic compartments of the cell. The molecules that interact with microbe-derived ligands trigger signaling pathways that lead to inflammatory responses. Harnessing the coordinated regulation of immune responses elicited by TLRs and helicases is a major focus of new adjuvant development for vaccines.

Citation: Ledgerwood J, Graham B. 2017. Immunization Against Viral Diseases, p 351-370. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch17
Permissions and Reprints Request Permissions
Download as Powerpoint


1. CDC . 2015. Measles Outbreak—California, December 2014–February 2015. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6406a5.htm. Accessed on July 13, 2015.
2. CDC . 2015. Measles—United States, January 4–April 2, 2015. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6414a1.htm. Accessed on July 13, 2015.
3. Graham BS, Ambrosino DM . 2015. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS 10 : 129 134.[PubMed]
4. Ault KA Future II Study Group . 2007. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 : 1861 1868.[PubMed]
5. Andre FE . 1990. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 8 Suppl : S74 80.
6. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL Shingles Prevention Study Group . 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 : 2271 2284.[PubMed]
7. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC ZOE-50 Study Group . 2015. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372 : 2087 2096.[PubMed]
8. CDC . 2015. Update on vaccine-derived polioviruses—worldwide, January 2014–March 2015. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6423a4.htm. Accessed on December 11, 2015
9. Schoub BD . 2012. Introduction of inactivated polio vaccine (IPV) into the routine immunization schedule of South Africa. Vaccine 30( Suppl 3) : C35 C37.[PubMed]
10. Medzhitov R, Janeway CA Jr . 2002. Decoding the patterns of self and nonself by the innate immune system. Science 296 : 298 230.[PubMed]
11. Barton GM . 2007. Viral recognition by Toll-like receptors. Semin Immunol 19 : 33 40.[PubMed]
12. Bowie AG, Fitzgerald KA . 2007. RIG-I: tri-ing to discriminate between self and non-self RNA. Trends Immunol 28 : 147 15.[PubMed]
13. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW . 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1 : 398 401.[PubMed]
14. Fox CB, Kramer RM, Barnes V L, Dowling QM, Vedvick TS . 2013. Working together: interactions between vaccine antigens and adjuvants. Ther Adv Vaccines 1 : 7 20.[PubMed]
15. Savelkoul HF, Ferro VA, Strioga MM, Schijns VE . 2015. Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines (Basel) 3 : 148 171.[PubMed]
16. McKeage K, Romanowski B . 2011. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 71 : 465 488.[PubMed]
17. Loré K, Adams WC, Havenga MJ, Precopio ML, Holterman L, Goudsmit J, Koup RA . 2007. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 179 : 1721 1729.[PubMed]
18. Wang R, Murphy KM, Loh DY, Weaver C, Russell JH . 1993. Differential activation of antigen-stimulated suicide and cytokine production pathways in CD4+ T cells is regulated by the antigen-presenting cell. J Immunol 150 : 3832 3842.[PubMed]
19. Lee S, Nguyen MT . 2015. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw 15 : 51 57.[PubMed]
20. Levast B, Awate S, Babiuk L, Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S . 2014. Vaccine potentiation by combination adjuvants. Vaccines (Basel) 2 : 297 322.[PubMed]
21. Bagnoli F, Fontana MR, Soldaini E, Mishra RP, Fiaschi L, Cartocci E, Nardi-Dei V, Ruggiero P, Nosari S, De Falco MG, Lofano G, Marchi S, Galletti B, Mariotti P, Bacconi M, Torre A, Maccari S, Scarselli M, Rinaudo CD, Inoshima N, Savino S, Mori E, Rossi-Paccani S, Baudner B, Pallaoro M, Swennen E, Petracca R, Brettoni C, Liberatori S, Norais N, Monaci E, Bubeck Wardenburg J, Schneewind O, O'Hagan DT, Valiante NM, Bensi G, Bertholet S, De Gregorio E, Rappuoli R, Grandi G . 2015. Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc Natl Acad Sci USA 112 : 3680 3685.[PubMed]
22. Seder R, Reed SG, O'Hagan D, Malyala P, D'Oro U, Laera D, Abrignani S, Cerundolo V, Steinman L, Bertholet S . 2015. Gaps in knowledge and prospects for research of adjuvanted vaccines. Vaccine 33( Suppl 2) : B40 B43.[PubMed]
23. Graham BS, Crow JE . 2007. Immunization Against Viral Diseases, 5th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia.
24. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR . 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 : 101 104.[PubMed]
25. Sallusto F, Lanzavecchia A, Araki K, Ahmed R . 2010. From vaccines to memory and back. Immunity 33 : 451 463.[PubMed]
26. Becht H, Hämmerling U, Rott R . 1971. Undisturbed release of influenza virus in the presence of univalent antineuraminidase antibodies. Virology 46 : 337 343.[PubMed]
27. Kim JH, Davis WG, Sambhara S, Jacob J . 2012. Strategies to alleviate original antigenic sin responses to influenza viruses. Proc Natl Acad Sci USA 109 : 13751 13756.[PubMed]
28. Lu Y, Welsh JP, Swartz JR . 2014. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci USA 111 : 125 130.[PubMed]
29. Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A . 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120 : 1663 1673.[PubMed]
30. Wheatley AK, Whittle JR, Lingwood D, Kanekiyo M, Yassine HM, Ma SS, Narpala SR, Prabhakaran MS, Matus-Nicodemos RA, Bailer RT, Nabel GJ, Graham BS, Ledgerwood JE, Koup RA, McDermott AB . 2015. H5N1 vaccine-elicited memory B cells are genetically constrained by the IGHV locus in the recognition of a neutralizing epitope in the hemagglutinin Stem. J Immunol 195 : 602 610.[PubMed]
31. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, de Man M, Ding Z, Apetri A, Kükrer B, Sneekes-Vriese E, Tomkiewicz D, Laursen NS, Lee PS, Zakrzewska A, Dekking L, Tolboom J, Tettero L, van Meerten S, Yu W, Koudstaal W, Goudsmit J, Ward AB, Meijberg W, Wilson IA, Radošević K . 2015. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349 : 1301 1306.[PubMed]
32. Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, Gallagher JR, Wang L, Zhang Y, Joyce MG, Lingwood D, Moin SM, Andersen H, Okuno Y, Rao SS, Harris AK, Kwong PD, Mascola JR, Nabel GJ, Graham BS . 2015. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21 : 1065 1070.[PubMed]
33. Spriggs MK . 1996. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol 14 : 101 130.[PubMed]
34. Perfetto SP, Chattopadhyay PK, Roederer M . 2004. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 4 : 648 655.[PubMed]
35. Chattopadhyay PK, Roederer M . 2015. A mine is a terrible thing to waste: high content, single cell technologies for comprehensive immune analysis. Am J Transplant 15 : 1155 1161.[PubMed]
36. Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK . 2012. A deep profiler's guide to cytometry. Trends Immunol 33 : 323 332.[PubMed]
37. Bjornson ZB, Nolan GP, Fantl WJ . 2013. Single-cell mass cytometry for analysis of immune system functional states. Curr Opin Immunol 25 : 484 494.[PubMed]
38. Dominguez MH, Chattopadhyay PK, Ma S, Lamoreaux L, McDavid A, Finak G, Gottardo R, Koup RA, Roederer M . 2013. Highly multiplexed quantitation of gene expression on single cells. J Immunol Methods 391 : 133 145.[PubMed]
39. Lee JY, Love PE . 2016. Assessment of T cell development by flow cytometry. Methods Mol Biol 1323 : 47 64.[PubMed]
40. Bashford-Rogers RJ, Palser AL, Idris SF, Carter L, Epstein M, Callard RE, Douek DC, Vassiliou GS, Follows GA, Hubank M, Kellam P . 2014. Capturing needles in haystacks: a comparison of B-cell receptor sequencing methods. BMC Immunol 15 : 29.[PubMed]
41. De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, Evans TG, Koup R, Miller CJ, Roederer M . 2004. Vaccination in humans generates broad T cell cytokine responses. J Immunol 173 : 5372 5380.[PubMed]
42. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M Jr, Lifson JD, Picker LJ . 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473 : 523 527[CrossRef].[PubMed]
43. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E . 2014. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 6 : 261ra153.[PubMed]
44. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, Foulds KE, Cheng C, Wang L, Donaldson MM, Colloca S, Folgori A, Roederer M, Nabel GJ, Mascola J, Nicosia A, Cortese R, Koup RA, Sullivan NJ . 2014. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 20 : 1126 1129; advance online publication.[PubMed]
45. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham BS VRC Study Team. 2014. Chimpanzee adenovirus vector Ebola vaccine—preliminary report. N Engl J Med. DOI: 10.1056/NEJMoa1410863 http://dx.doi.org/DOI: 10.1056/NEJMoa1410863
46. Park CO, Kupper TS . 2015. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med 21 : 688 697.[PubMed]
47. Smith CJ, Turula H, Snyder CM . 2014. Systemic hematogenous maintenance of memory inflation by MCMV infection. PLoS Pathog 10 : e1004233.[PubMed]
48. Barouch DH, Picker LJ . 2014. Novel vaccine vectors for HIV-1. Nat Rev Microbiol 12 : 765 771.[PubMed]
49. Murphy KM, Reiner SL . 2002. The lineage decisions of helper T cells. Nat Rev Immunol 2 : 933 944.[PubMed]
50. Stockinger B, Kassiotis G, Bourgeois C . 2004. CD4 T-cell memory. Semin Immunol 16 : 295 303.[PubMed]
51. Douek DC, Picker LJ, Koup RA . 2003. T cell dynamics in HIV-1 infection. Annu Rev Immunol 21 : 265 304.[PubMed]
52. Zhu J, Yamane H, Paul WE . 2010. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28 : 445 489.[PubMed]
53. Crotty S . 2015. A brief history of T cell help to B cells. Nat Rev Immunol 15 : 185 189.[PubMed]
54. McElhaney JE, Hooton JW, Hooton N, Bleackley RC . 2005. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 23 : 3294 3300.[PubMed]
55. Dhiman N, Ovsyannikova IG, Ryan JE, Jacobson RM, Vierkant RA, Pankratz VS, Jacobsen SJ, Poland GA . 2005. Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination. Clin Exp Immunol 142 : 498 504.[PubMed]
56. Hasenkrug KJ, Brooks DM, Dittmer U . 1998. Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol 72 : 6559 6564.[PubMed]
57. Manickan E, Francotte M, Kuklin N, Dewerchin M, Molitor C, Gheysen D, Slaoui M, Rouse BT . 1995. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J Virol 69 : 4711 4716.[PubMed]
58. Mozdzanowska K, Furchner M, Maiese K, Gerhard W . 1997. CD4+ T cells are ineffective in clearing a pulmonary infection with influenza type A virus in the absence of B cells. Virology 239 : 217 225.[PubMed]
59. Topham DJ, Doherty PC . 1998. Clearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells. J Virol 72 : 882 885.[PubMed]
60. Kündig TM, Castelmur I, Bachmann MF, Abraham D, Binder D, Hengartner H, Zinkernagel RM . 1993. Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus. J Virol 67 : 3680 3683.[PubMed]
61. Wu CY, Kirman JR, Rotte MJ, Davey DF, Perfetto SP, Rhee EG, Freidag BL, Hill BJ, Douek DC, Seder RA . 2002. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol 3 : 852 858.[PubMed]
62. Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L, Sato T, Reed JC, Green D, Swain SL . 1997. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 185 : 1837 1849.[PubMed]
63. Belkaid Y, Rouse BT . 2005. Natural regulatory T cells in infectious disease. Nat Immunol 6 : 353 360.[PubMed]
64. Weinberg A, Muresan P, Richardson KM, Fenton T, Dominguez T, Bloom A, Watts DH, Abzug MJ, Nachman SA, Levin MJ P1086 Team . 2015. Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine. PLoS One 10 : e0122431.[PubMed]
65. Weinberg A, Muresan P, Fenton T, Richardson K, Dominguez T, Bloom A, Petzold E, Anthony P, Cunningham CK, Spector SA, Nachman S, Siberry GK, Handelsman E, Flynn PM IMPAACT P1088 Study Team . 2013. High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088). Hum Vaccin Immunother 9 : 957 968.[PubMed]
66. Srivastava S, Koch MA, Pepper M, Campbell DJ . 2014. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med 211 : 961 974.[PubMed]
67. Laidlaw BJ, Cui W, Amezquita RA, Gray SM, Guan T, Lu Y, Kobayashi Y, Flavell RA, Kleinstein SH, Craft J, Kaech SM . 2015. Production of IL-10 by CD4(+) regulatory T cells during the resolution of infection promotes the maturation of memory CD8(+) T cells. Nat Immunol 16 : 871 879.[PubMed]
68. Sholukh AM, Watkins JD, Vyas HK, Gupta S, Lakhashe SK, Thorat S, Zhou M, Hemashettar G, Bachler BC, Forthal DN, Villinger F, Sattentau QJ, Weiss RA, Agatic G, Corti D, Lanzavecchia A, Heeney JL, Ruprecht RM . 2015. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 33 : 2086 2095.[PubMed]
69. MedImmune . 2015. FluMist package insert. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM294307.pdf. Accessed on December 11, 2015.
70. Tuero I, Mohanram V, Musich T, Miller L, Vargas-Inchaustegui DA, Demberg T, Venzon D, Kalisz I, Kalyanaraman VS, Pal R, Ferrari MG, LaBranche C, Montefiori DC, Rao M, Vaccari M, Franchini G, Barnett SW, Robert-Guroff M . 2015. Mucosal B cells are associated with delayed SIV acquisition in vaccinated female but not male rhesus macaques following SIVmac251 rectal challenge. PLoS Pathog 11 : e1005101.[PubMed]
71. Tan HX, Kent SJ, De Rose R . 2015. Contemporary HIV vaccines: Tissue resident T-cells and strategies to prevent mucosal infection. Curr Top Med Chem 16 : 1107 1117.[PubMed]
72. Singh S, Nehete PN, Yang G, He H, Nehete B, Hanley PW, Barry MA, Sastry KJ . 2014. Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant. Vaccines (Basel) 2 : 686 706.[PubMed]
73. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L . 2007. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 204 : 595 603.[PubMed]
74. Mehrishi JN, Szabó M, Bakács T . 2007. Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials. Vaccine 25 : 3517 3523.[PubMed]
75. Ma R, Du JL, Huang J, Wu CY . 2007. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem Biophys Res Commun 361 : 537 542.[PubMed]
76. Wille-Reece U, Flynn BJ, Loré K, Koup RA, Miles AP, Saul A, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA . 2006. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203 : 1249 1258.[PubMed]
77. Schiller JT, Lowy DR . 2012. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 10 : 681 692[CrossRef].[PubMed]
78. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, Shaw GM . 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201 : 1407 1419.[PubMed]
79. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD . 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 : 732 737.[PubMed]
80. Kwong PD, Mascola JR . 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37 : 412 425.[PubMed]
81. Graham BS . 2013. Advances in antiviral vaccine development. Immunol Rev 255 : 230 242.[PubMed]
82. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS . 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340 : 1113 1117.[PubMed]
83. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD . 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342 : 592 598.[PubMed]
84. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, Macpherson S, Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe JE Jr, Johnson PR, Schief WR . 2014. Proof of principle for epitope-focused vaccine design. Nature 507 : 201 206.[PubMed]
85. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM . 2004. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 : 2295 2301.[PubMed]
86. Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P . 2007. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 25 : 659 663.[PubMed]
87. Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL . 2007. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 119 : 1076 1082.[PubMed]
88. Ronish RH, Diniega BM, Kelley PW, Sjogren MH, Arday DR, Aronson NE, Hoke CH, Petruccelli BP . 1991. Immunogenicity achieved by the intradermal hepatitis B vaccination programme for US Army soldiers in Korea. Vaccine 9 : 364 368.[PubMed]
89. Beasley DW, Davis CT, Whiteman M, Granwehr B, Kinney RM, Barrett AD . 2004. Molecular determinants of virulence of West Nile virus in North America. Arch Virol Suppl 18 : 35 41.[PubMed]
90. Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R . 2006. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 24 : 4490 4493.[PubMed]
91. Otten GR, Schaefer M, Doe B, Liu H, Megede JZ, Donnelly J, Rabussay D, Barnett S, Ulmer JB . 2006. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 24 : 4503 4509.[PubMed]
92. Khurana S, Needham J, Park S, Mathieson B, Busch MP, Nemo G, Nyambi P, Zolla-Pazner S, Laal S, Mulenga J, Chomba E, Hunter E, Allen S, McIntyre J, Hewlett I, Lee S, Tang S, Cowan E, Beyrer C, Altfeld M, Yu XG, Tounkara A, Koita O, Kamali A, Nguyen N, Graham BS, Todd D, Mugenyi P, Anzala O, Sanders E, Ketter N, Fast P, Golding H . 2006. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. J Acquir Immune Defic Syndr 43 : 304 312.[PubMed]
93. Greenland JR, Letvin NL . 2007. Chemical adjuvants for plasmid DNA vaccines. Vaccine 25 : 3731 3741.[PubMed]
94. Zhou X, Zhang X, Yu X, Zha X, Fu Q, Liu B, Wang X, Chen Y, Chen Y, Shan Y, Jin Y, Wu Y, Liu J, Kong W, Shen J . 2008. The effect of conjugation to gold nanoparticles on the ability of low molecular weight chitosan to transfer DNA vaccine. Biomaterials 29 : 111 117.[PubMed]
95. Brinkman DM, Jol-van der Zijde CM, ten Dam MM, Vossen JM, Osterhaus AD, Kroon FP, van Tol MJ . 2003. Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man. J Clin Immunol 23 : 528 538.[PubMed]
96. Schmidtke P, Habermehl P, Knuf M, Meyer CU, Sänger R, Zepp F . 2005. Cell mediated and antibody immune response to inactivated hepatitis A vaccine. Vaccine 23 : 5127 5132.[PubMed]
97. Watson B, Rothstein E, Bernstein H, Arbeter A, Arvin A, Chartrand S, Clements D, Kumar ML, Reisinger K, Blatter M, Starr SE, Staehle B, Ngai A, White CJ . 1995. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 172 : 217 219.[PubMed]
98. Holodniy M . 2006. Prevention of shingles by varicella zoster virus vaccination. Expert Rev Vaccines 5 : 431 443.[PubMed]
99. Jarrosson L, Kolopp-Sarda MN, Aguilar P, Béné MC, Lepori ML, Vignaud MC, Faure GC, Kohler C . 2004. Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses. Vaccine 22 : 3789 3796.[PubMed]
100. Woodland DL . 2004. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25 : 98 104.[PubMed]
101. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, Miura A, Sambor A, Chakrabarti BK, Huang Y, Bailer R, Koup RA, Mascola JR, Nabel GJ, Letvin NL . 2005. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79 : 2956 2963.[PubMed]
102. Hijnen M, van Zoelen DJ, Chamorro C, van Gageldonk P, Mooi FR, Berbers G, Liskamp RM . 2007. A novel strategy to mimic discontinuous protective epitopes using a synthetic scaffold. Vaccine 25 : 6807 6817.[PubMed]
103. Hadler SC, de Monzon MA, Lugo DR, Perez M . 1989. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 7 : 106 110.[PubMed]
104. Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Pearce MB, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS VRC 304 and VRC 305 Study Teams . 2012. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 19 : 1792 1797.[PubMed]
105. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS Team VRCS , VRC 306 Study Team . 2011. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 11 : 916 924.[PubMed]
106. Ledgerwood JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Graham BS VRC 310 Study Team . 2013. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 208 : 418 422.[PubMed]
107. Grayson JM, Harrington LE, Lanier JG, Wherry EJ, Ahmed R . 2002. Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. J Immunol 169 : 3760 3770.[PubMed]
108. Ogra PL . 1995. Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines. Ann N Y Acad Sci 754( 1 Combined Vacc) : 97 107.[PubMed]
109. Vessey SJ, Chan CY, Kuter BJ, Kaplan KM, Waters M, Kutzler DP, Carfagno PA, Sadoff JC, Heyse JF, Matthews H, Li S, Chan IS . 2001. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr 139 : 297 304.[PubMed]
110. Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, Saville MK, Cho I, Razmpour A, Rappaport R, O'Neill R, Georgiu A, Gruber W, Mendelman PM, Forrest B CAIV-T Transmission Study Group . 2006. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 25 : 590 595.[PubMed]
111. Armstrong ME, Giesa PA, Davide JP, Redner F, Waterbury JA, Rhoad AE, Keys RD, Provost PJ, Lewis JA . 1993. Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F. J Hepatol 18( Suppl 2) : S20 S26.[PubMed]
112. Stephenne J . 1990. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 8(Suppl) : S69 S80.
113. Lunn ER, Hoggarth BJ, Cook WJ . 2000. Prolonged hepatitis B surface antigenemia after vaccination. Pediatrics 105 : e81.[PubMed]
114. Kushnir N, Streatfield SJ, Yusibov V . 2012. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31 : 58 83.[PubMed]
115. Wu T, Li SW, Zhang J, Ng MH, Xia NS, Zhao Q . 2012. Hepatitis E vaccine development: a 14 year odyssey. Hum Vaccin Immunother 8 : 823 827.[PubMed]
116. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW, Xia NS . 2010. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376 : 895 902.[PubMed]
117. Zhang X, Wei M, Pan H, Lin Z, Wang K, Weng Z, Zhu Y, Xin L, Zhang J, Li S, Xia N, Zhao Q . 2014. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®). Vaccine 32 : 4039 4050.[PubMed]
118. Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE Team VRCS , VRC 311 Study Team . 2014. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 384 : 2046 2052.[PubMed]
119. FDA . 2010. Guidance for industry: characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM202439.pdf. Accessed on November 13, 2015.
120. FDA . 2015. Thimerosal in vaccines. http://www.fda.gov/cber/vaccine/thimerosal.htm. Accessed on November 13, 2015
121. Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, Lewis E, Eriksen E, Ray P, Marcy SM, Dunn J, Jackson LA, Lieu TA, Black S, Stewart G, Weintraub ES, Davis RL, DeStefano F Vaccine Safety Datalink Team . 2007. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 357 : 1281 1292.[PubMed]
122. CDC . May 18, 2006. Update: multistate outbreak of mumps—United States, January 1—May 2, 2006. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm55d518a1.htm. Accessed on May 19, 2015
123. CDC . 2015. Measles cases and outbreaks. http://www.cdc.gov/measles/cases-outbreaks.html. Accessed on July 23, 2015.
124. Taylor LE, Swerdfeger AL, Eslick GD . 2014. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine 32 : 3623 3629.[PubMed]
125. Offit PA, Coffin SE . 2003. Communicating science to the public: MMR vaccine and autism. Vaccine 22 : 1 6.[PubMed]
126. Calandrillo SP . 2004. Vanishing vaccinations: why are so many Americans opting out of vaccinating their children? Univ Mich J Law Reform 37 : 353 440.[PubMed]
127. Constable C, Blank NR, Caplan AL . 2014. Rising rates of vaccine exemptions: problems with current policy and more promising remedies. Vaccine 32 : 1793 1797.[PubMed]
128. Domachowske JB, Suryadevara M . 2013. Practical approaches to vaccine hesitancy issues in the United States: 2013. Hum Vaccin Immunother 9 : 2654 2657.[PubMed]
129. Salmon DA, Dudley MZ, Glanz JM, Omer SB . 2015. Vaccine hesitancy: Causes, consequences, and a call to action. Am J Prev Med 49( Suppl 4) : S391 S398.[PubMed]
130. Omer SB, Pan WK, Halsey NA, Stokley S, Moulton LH, Navar AM, Pierce M, Salmon DA . 2006. Nonmedical exemptions to school immunization requirements: secular trends and association of state policies with pertussis incidence. JAMA 296 : 1757 1763.[PubMed]
131. Diekema DS . 2014. Personal belief exemptions from school vaccination requirements. Annu Rev Public Health 35 : 275 292.[PubMed]
132. Wang E, Clymer J, Davis-Hayes C, Buttenheim A . 2014. Nonmedical exemptions from school immunization requirements: a systematic review. Am J Public Health 104 : e62 e84.[PubMed]
133. Brydak LB, Rokicka-Milewska R, Machała M, Jackowska T, Sikorska-Fic B . 1998. Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukemia. Pediatr Infect Dis J 17 : 125 129.[PubMed]
134. Karahocagil MK, Buzgan T, Irmak H, Karsen H, Akdeniz H, Akman N . 2006. Comparison of intramuscular and intradermal applications of hepatitis B vaccine in hemodialysis patients. Ren Fail 28 : 561 565.[PubMed]
135. CDC . 2014. Vaccines for pregnant women. http://www.cdc.gov/vaccines/adults/rec-vac/pregnant.html. Accessed on December 11, 2015.
136. HRSA . Vaccine injury table. http://www.hrsa.gov/vaccinecompensation/vaccinetable.html Accessed on November 13, 2015.
137. CDC . Multi-, routine-, & non-routine-vaccine VISs. http://www.cdc.gov/vaccines/hcp/vis/index.html. Accessed
138. Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN . 2004. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 43 : 1503 1510.[PubMed]
139. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH . 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89 : 449 463.[PubMed]
140. Dudas RA, Karron RA . 1998. Respiratory syncytial virus vaccines. Clin Microbiol Rev 11 : 430 439.[PubMed]
141. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, Rodriguez WJ, Chanock RM . 1986. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 24 : 197 202.[PubMed]
142. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, Lirman DD, Rabold R, Hoffman SJ, Karp CL, Kleeberger SR, Wills-Karp M, Karron RA . 2002. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196 : 859 865.[PubMed]
143. Kim HW, Leikin SL, Arrobio J, Brandt CD, Chanock RM, Parrott RH . 1976. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 10 : 75 78.[PubMed]
144. Johnson TR, Parker RA, Johnson JE, Graham BS . 2003. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol 170 : 2037 2045.[PubMed]
145. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, Zanardi LR, Setia S, Fair E, LeBaron CW, Wharton M, Livengood JR Rotavirus Intussusception Investigation Team . 2001. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344 : 564 572.[PubMed]
146. Murphy BR, Morens DM, Simonsen L, Chanock RM, La Montagne JR, Kapikian AZ . 2003. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 187 : 1301 1308.[PubMed]
147. Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM, La Montagne JR, Murphy BR . 2005. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis 192( Suppl 1) : S22 S29.[PubMed]